What CELNOVA PHARMA does

Celnova Pharma is a privately held regional pharmaceutical company founded in 2012 and headquartered in San Isidro, Buenos Aires, Argentina. It specializes in complex therapeutic classes — oncology and onco-hematology, central nervous system disorders, diabetes, critical care, and rare/orphan diseases — and operates wholly-owned subsidiaries in Argentina, Chile, Colombia, Peru, and Uruguay, with remote commercial presence in Bolivia, Ecuador, and Paraguay. The company markets branded and generic prescription products including SYNTOCINON, VORINOVA, Riluzol oral suspension, Levetiracetam, Dantrolene Sodium, and Apomorphine, and serves as the exclusive regional distributor for originator products such as Alnylam's patisiran (Argentina) and givosiran (Colombia). Core technology is not publicly disclosed; the company does not publish APIs, SDKs, or AI-driven features.

The company's go-to-market is a proprietary enterprise field-sales model that reaches specialist physicians (oncologists, neurologists, endocrinologists, critical-care specialists) and specialized buyers directly across all operating markets. It supplements this with a gated scientific content portal for validated healthcare professionals, the Celnova Asiste patient assistance program (Argentina and Chile), and multi-disease Comunidad Celnova patient communities. Revenue is generated through prescription pharmaceutical sales across multiple therapeutic franchises, distributed via its own commercial infrastructure and strategic channel partnerships with Novartis and Norgine. Pricing is not publicly disclosed, consistent with prescription-pharma industry norms.

Strategically, 2024 was an active expansion year: Celnova launched four products in Argentina and signed distribution agreements with Alnylam Pharmaceuticals, Novartis, and Norgine. No funding rounds, acquisitions, or leadership changes are documented in the source data, and the company appears independently owned with no disclosed parent or institutional investor. Headcount is 51-100 employees, and revenue is not publicly reported.

Name

CELNOVA PHARMA

Legal name

Celnova Argentina S.A.

Website

https://celnova.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Celnova Pharma is a privately held regional pharmaceutical company that markets prescription medicines in oncology, CNS, diabetes, critical care, and rare diseases across eight Latin American countries, serving specialist physicians through its own commercial team and strategic originator partnerships.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Prescription medicines
• Oncology therapeutics
• Rare disease treatments
• Central nervous system drugs

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical prescription medicines: Celnova Pharma generates revenue through the sale of prescription-only pharmaceutical products across complex therapeutic areas including oncology, central nervous system, diabetes, critical care, and rare diseases. Products are distributed across multiple Latin American countries via the company's own commercial infrastructure and distribution partnerships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Celnova Pharma markets and distributes a portfolio of prescription-only pharmaceutical products across complex therapeutic areas including oncology and onco-hematology, central nervous system disorders, diabetes, critical care, and rare/orphan diseases. The company sells its medicines through a proprietary commercial team and strategic distribution partnerships to specialist physicians, hospitals, and specialized buyers across Argentina, Chile, Colombia, Peru, Uruguay, and additional Latin American markets.

Product overview

Celnova Pharma is a regional pharmaceutical company specializing in complex therapeutic areas. The company offers a portfolio of prescription pharmaceutical products across five main therapeutic areas: Central Nervous System (covering Parkinson's disease, Epilepsy, and ALS), Diabetes, Oncology and Onco-Hematology, Rare Diseases (including Carcinoma Adrenocortical, Cushing's Syndrome, Amyloidosis, and Porphyria), and Critical Care. Core products include SYNTOCINON® (oxytocin injection/nasal spray), VORINOVA® (voriconazole antifungal), along with recently launched products such as Riluzol oral suspension, Levetiracetam, Dantrolene Sodium, and Apomorphine. The company also distributes specialty medicines including Patisirán and Givosiran under partnerships with Alnylam Pharmaceuticals. Celnova operates a healthcare professional portal providing scientific content and patient support programs including Celnova Asiste.

Differentiator

Problem solved

Functional benefit

Brands

• Celnova Asiste: Patient assistance program designed for patients using Celnova products for their treatment
• Comunidad Celnova

Products and services

• SYNTOCINON Oxytocin-based pharmaceutical product available as 5 UI injection solution and 40 UI nasal spray, indicated for prepartum uses (labor induction, uterine inertia, incomplete abortion) and postpartum uses (cesarean section, prevention/treatment of uterine atony and postpartum hemorrhage).
• VORINOVA Voriconazole 200 mg broad-spectrum triazole antifungal available as coated tablets and powder for perfusion solution, indicated for invasive aspergillosis, candidemia in non-neutropenic patients, invasive candidiasis (including C. krusei), Scedosporium and Fusarium infections, and prophylaxis in high-risk hematopoietic stem cell transplant recipients.
• Riluzol Oral Suspension Riluzol in oral suspension formulation indicated for the treatment of Amyotrophic Lateral Sclerosis (ALS), launched in Argentina in 2024.
• Levetiracetam Antiepileptic medication available in two presentations, launched in Argentina in 2024 for the treatment of epilepsy.
• Dantrolene Sodium Muscle relaxant medication available in two presentations, launched in Argentina in 2024 for critical care applications.
• Apomorphine Dopamine agonist indicated for the treatment of Parkinson's disease, with a new presentation available in Argentina in 2024.
• Patisirán RNAi therapeutic agent indicated for hereditary transthyretin-mediated (hATTR) amyloidosis, distributed exclusively by Celnova Pharma in Argentina under an Alnylam Pharmaceuticals partnership.
• Givosiran RNAi therapeutic agent indicated for Acute Hepatic Porphyria, distributed exclusively by Celnova Pharma in Colombia under an Alnylam Pharmaceuticals partnership.
• Celnova Asiste Patient Assistance Program Patient support program designed and directed at patients using Celnova products for the treatment of their pathologies, providing support, adherence resources, and educational content. Available in Argentina and Chile.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Alnylam PharmaceuticalscoreChannel Partner/ Reseller/ DistributorCelnova Pharma was selected by Alnylam Pharmaceuticals as the exclusive distributor of patisiran (for the treatment of hereditary transthyretin-mediated amyloidosis) in Argentina, and as the exclusive distributor of givosiran in Colombia.
• NovartiscoreChannel Partner/ Reseller/ DistributorCelnova Pharma entered into an agreement with Novartis in Argentina for the distribution of pharmaceutical products.
• NorgineminorChannel Partner/ Reseller/ DistributorCelnova Pharma announced a distribution agreement with Norgine for the distribution of pharmaceutical products.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Gador: Argentine specialty pharma focused on CNS and hospital/critical care segments; competes in overlapping therapeutic areas and Argentinian HCP relationships.
• Roemmers: Major Argentine pharmaceutical company with branded specialty products and regional expansion; competes with Celnova in CNS, cardiology and women's health.
• Eurofarma: Latin America's largest privately held pharmaceutical company, with broad specialty and branded prescription coverage across Brazil and other LatAm markets; a direct competitor for innovator distribution partnerships and specialty launches.
• Laboratorios Raffo: Argentine specialty pharma with branded innovative and specialty products; comparable regional peer for branded prescription marketing in overlapping therapeutic areas.
• Megalabs: Latin American specialty pharmaceutical company with proprietary products and distribution across multiple therapeutic areas and countries; competes directly with Celnova for regional share-of-voice with specialists.
• Laboratorios Bagó: Argentine-headquartered pharma group with branded specialty products and pan-LatAm commercial reach; one of the closest country-of-origin competitors for Celnova's home market.
• Laboratorios Richmond: Argentine pharmaceutical company with branded specialty and innovative products; comparable home-market competitor with overlapping CNS, oncology and rare disease exposure.

Others

• Alnylam Pharmaceuticals: Innovator of the RNAi therapeutics (patisiran, givosiran) that Celnova distributes exclusively in Argentina and Colombia; relevant as supplier/partner rather than competitor, illustrating the type of originator Celnova's platform targets.

Broad incumbents

• Teva Pharmaceutical Industries: Global specialty and generics company that also markets CNS and oncology products in LatAm through local partners; a broader incumbent whose specialty division overlaps with Celnova's CNS focus.
• Sanofi (Latin America): Multinational pharma with deep specialty and rare-disease presence (Genzyme) in Latin America; competes with Celnova's rare disease and oncology franchises and could partner or compete depending on indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/celnovapharma
• Facebookfacebook.com/Celnova-Pharma-100817968441444
• LinkedInlinkedin.com/company/celnova-pharma
• Instagraminstagram.com/celnova_pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CELNOVA PHARMA